Invivo Therapeutics
NVIV

From December 31, 2022 to March 31, 2023 Issuance of common stock upon exercise of warrants

From December 31, 2021 to December 31, 2022 Issuance of common stock upon exercise of prefunded warrants Forfeiture of restricted stock Fractional shares issued due to 1 for 25 reverse stock split Issuance of common stock and warrants in public offering

the company is offering 154,000 shares common stock

From March 31, 2022 to June 30, 2022 Forfeiture of restricted stock Fractional shares issued due to 1 for 25 reverse stock split

On April 14, 2022, the Board of Directors of InVivo Therapeutics Holdings Corp. (the “Company”) approved a 1-for-25 reverse stock split of the Company’s authorized shares of common stock, par value $0.00001 per share (the “Common Stock”), accompanied by a corresponding decrease in the Company’s issued and outstanding shares of Common Stock (the “Reverse Stock Split”), such that, following the consummation of the Reverse Stock Split, the number of authorized shares of Common Stock shall be reduced from 50,000,000 to 2,000,000.

From December 31, 2020 to December 31, 2021 Issuance of common stock upon vesting of restricted stock units Issuance of common stock upon exercise of warrants

From March 31, 2021 to June 30, 2021 Issuance of common stock upon vesting of restricted stock units

From December 31, 2020 To March 31, 2021 Issuance of common stock upon exercise of warrants

From December 31,2019 to December 31,2020 Issuance of common stock upon vesting of restricted stock units Fractional shares issued due to 1 for 30 reverse stock split Forfeiture of restricted stock Issuance of common stock and warrants in public offering Issuance of common stock upon exercise of warrants

1.Securities offered by the company in this offering: 11,785,000 shares of common stock and Series A warrants to purchase 11,785,000 shares of common stock, and 6,965,000 Series B pre-funded warrants to purchase shares of common stock and Series A warrants to purchase 6,965,000 shares of common stock. 2.The number of shares of common stock to be outstanding immediately after this offering is based on 4,882,420 shares of common stock outstanding as of September 30, 2020.

From March 31, 2020 to June 30, 2020 Issuance of common stock upon vesting of restricted stock units Issuance of common stock and warrants in public offering Issuance of common stock upon exercise of warrants

1.Securities offered by us: 1,715,240 shares of our common stock 2.The number of shares of common stock to be outstanding immediately after this offering is based on 3,132,130 shares of our common stock outstanding as of April 14, 2020

From December 31, 2019 to March 31, 2020 Fractional shares issued due to 1 for 30 reverse stock split Issuance of common stock and warrants in public offering Issuance of common stock upon exercise of warrants

On March 10, 2020, InVivo Therapeutics Holdings Corp. (the "Company") completed a registered public offering (the "Offering") in which it sold an aggregate of (i) 955,613 shares of common stock, $0.00001 par value per share, of the Company (the "Shares"), (ii) Series B warrants (the "Series B Warrants") exercisable for an aggregate of 1,589,842 shares of common stock and (iii) Series A Warrants (the "Series A Warrants") exercisable for an aggregate of 2,545,455 shares of common stock (the Series A Warrants together with the Series B Warrants, the "Warrants") pursuant to a Placement Agency Agreement (the "Placement Agency Agreement") the Company entered into with H.C. Wainwright & Co., LLC ("Wainwright") on March 6, 2020.

From December 31, 2018 to February 12, 2020 Issuance of common stock upon vesting of restricted stock units Issuance of common stock under ESPP Issuance of restricted common stock Issuance of common stock and warrants in public offering On February 3, 2020, the Board of Directors of InVivo Therapeutics Holdings Corp. (the “Company”) approved a 1-for-30 reverse stock split of the Company’s authorized shares of common stock, par value $0.00001 per share (the “Common Stock”), accompanied by a corresponding decrease in the Company’s issued and outstanding shares of Common Stock (the “Reverse Stock Split”), such that, following the consummation of the Reverse Stock Split, the number of authorized shares of Common Stock shall be reduced from 500,000,000 to 16,666,667. The Reverse Stock Split will become effective at the effective time set forth in the Certificate of Change to be filed with the Secretary of State of the State of Nevada (the “Certificate of Change”).

from June 30, 2019 to September 30, 2019 Issuance of common stock upon vesting of restricted stock units Issuance of restricted common stock

From December 31, 2018 to June 30, 2019 Issuance of common stock upon vesting of restricted stock units Issuance of common stock under ESPP

From December 31, 2018 to March 22, 2019 Issuance of common stock upon vesting of restricted stock units Issuance of common stock under ESPP

from December 31, 2017 to December 31, 2018 Issuance of common stock upon vesting of restricted stock units Issuance of common stock upon exercise of warrants Issuance of common stock under ESPP Fractional shares issued due to reverse stock split Issuance of common stock to 401(k) plan Issuance of common stock in public offering

From June 30, 2018 to September 30, 2018 Issuance of common stock upon vesting of restricted stock units Issuance of common stock upon exercise of warrants Issuance of common stock under ESPP

On April 16, 2018, InVivo Therapeutics Holdings Corp. (the “Company”) effected a reverse stock split of the Company’s common stock, par value $0.00001 per share (the “Common Stock”), at a ratio of 1-for-25 (the “Reverse Split”). As a result of the Reverse Split, every 25 shares of the issued and outstanding Common Stock were automatically converted into one newly issued and outstanding share of Common Stock, without any change in the par value per share.

from December 31, 2016 to December 31, 2017 Issuance of common stock on warrant exchange Issuance of common stock for services Issuance of common stock upon exercise of warrants Issuance of common stock upon exercise of stock options Issuance of common stock under ESPP Issuance of common stock to 401(k) plan

from December 31, 2015 to December 31, 2016 Issuance of common stock and warrants in public offerings, net of $2,040 issuance costs Issuance of common stock for services Issuance of common stock upon cashless exercise of warrants Issuance of common stock upon exercise of stock options Issuance of common stock under ESPP Issuance of common stock to 401(k) plan

from December 31, 2014 to December 31, 2015 Issuance of common stock in public offerings Issuance of common stock upon exercise of warrants Issuance of common stock upon exercise of stock options Fractional shares issued due to reverse stock split Issuance of common stock to 401(k) plan